A minimally invasive treatment that involves irrigating the major salivary glands with corticosteroids, a type of anti-inflammatory medication, significantly reduced both objective and subjective measures of dry mouth in people with Sjögren’s disease, a small study showed. Greater benefits were observed among those with a higher symptom burden before…
News
Four genes involved in a form of cell death called pyroptosis are highly active in people with Sjögren’s disease and may serve as disease biomarkers or therapeutic targets, a study reports. By examining the activity of each of the genes — PECAM1, IFI16, AIM2, and MPEG1 —the researchers…
A new artificial intelligence (AI) tool has demonstrated the ability to significantly enhance the diagnosis of Sjögren’s disease by rapidly and accurately analyzing tissue samples, according to a multicenter European study. The AI system achieved an accuracy of more than 87% in classifying the focus score, which is the…
The severity of fatigue experienced by people with Sjögren’s disease affects their pain severity, and also has an impact on the effect of external factors, such as weather changes and loud noises, that can amplify a patient’s pain. That’s according to the findings of a single-center study in Italy,…
Two global Phase 3 clinical trials are now testing dazodalibep, Amgen’s experimental therapy for Sjögren’s disease, in two groups of adults. One of the studies is still recruiting participants. One of the trials, called HZNP-DAZ-301 (NCT06104124), has completed enrollment of 651 people with moderate-to-severe systemic (body-wide) Sjögren’s…
People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…
Sjögren’s disease patients found significant relief from debilitating symptoms like dryness, pain, and fatigue after treatment with Johnson & Johnson’s investigational antibody, nipocalimab, in a Phase 2 clinical trial. Full results from the study, dubbed DAHLIAS (NCT04969812), confirmed that nipocalimab treatment, compared to a placebo, not only…
An experimental therapy from Ouro Medicines is being tested in a Phase 1b clinical trial on people who have Sjögren’s disease or idiopathic inflammatory myopathy (IMM), another autoimmune condition. “This study reflects Ouro’s strategy of expanding OM336 development to additional immune-mediated diseases where an ‘immune reset’ approach would…
The investigational therapy telitacicept leads to significant and clinically meaningful reductions in disease activity and patient-reported symptoms among adults with primary Sjögren’s disease, according to new data from a Phase 3 clinical trial conducted in China. The findings — consistent with Phase 2 trial data — were…
A machine learning tool that can analyze certain molecules in stool samples may help to better diagnose primary Sjögren’s disease, according to a new study from researchers in China. The team found that their novel model, using fecal samples, could distinguish primary Sjögren’s patients from healthy individuals with an…
Recent Posts
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial
- Machine learning tool may help in diagnosing primary Sjögren’s